Seffalair® Spiromax® (salmeterol xinafoate / fluticasone propionate)

This information is only for patients who have been prescribed Seffalair® Spiromax® (salmeterol xinafoate / fluticasone propionate) inhaler

Seffalair® Spiromax® inhaler contains two different active substances: salmeterol xinafoate and fluticasone propionate.

Salmeterol is a long-acting bronchodilator. Bronchodilators help the airways open. This makes it easier for air to get in and out. The effects of salmeterol last for at least 12 hours.

Fluticasone propionate is a corticosteroid which reduces swelling and irriation in the lungs.

Seffalair® Spiromax® helps to prevent breathlessness and wheeziness coming on. You should not use it to relieve an asthma attack, use a fast-acting reliever (rescue) inhaler, such as salbutamol. You should always have your fast-acting rescue inhaler with you.

For more information please refer to the Patient Information Leaflet.

Seffalair® Spiromax® (salmeterol xinafoate / fluticasone propionate) inhaler - Instructions for use

Understanding your Patient Information Leaflet

Within the original packaging of all regulated medicines, you will find an important document called the Patient Information Leaflet. We recommend you read this document carefully and keep it for future reference.

The Patient Information Leaflet gives you key information to help you get the desired results from your medicine. Reading the Patient Information Leaflet is designed to supplement – not replace – discussions with your doctor, pharmacist or other healthcare professional about the medication. 

If for any reason your medicine has not come with this leaflet, you can ask for one from your pharmacist. Patient Information Leaflets are also available to download from Teva’s product list.

Go to product list

Get in touch with Teva

We're here to assist patients and healthcare professionals with information about our medicines, devices and services.

Teva UK Medical Information

Our Medical Information Service can help with enquiries about Teva's medicines, devices and services.

Tel: 0207 540 7117 
Email: medinfo@tevauk.com

They can also provide copies of regulatory documents such as Patient Information Leaflets, or Summary of Product Characteristics. These documents are also available to download from Teva’s product list.

Go to product list

Reporting Suspected Side Effects

For patients taking a Teva medicine: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. By reporting side effects you can help provide more information on the safety of a medicine.

Side effects can be reported to Teva:
Tel: 0207 540 7117
Email: 
uk.safety@tevauk.com
Online: Side Effect Reporting Form

You can also report side effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard

Life Effects™ - By patients, for patients

The only people who really know what you’re going through are other patients like you. Through Teva’s Life Effects™ website you can read stories, tips and real life experiences from other patients living with respiratory conditions.

Discover more Life Effects™ - By patients, for patients
Date of preparation: July 2022
Reference: SEF-GB-NP-00002